Genentech Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GENENTECH INC
GENENTECH INC has eight approved drugs.
There are forty-five US patents protecting GENENTECH INC drugs.
Summary for Genentech Inc
| US Patents: | 45 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 8 |
Drugs and US Patents for Genentech Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | ROZLYTREK | entrectinib | PELLETS;ORAL | 218550-001 | Oct 20, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-001 | Aug 15, 2019 | RX | Yes | No | 10,561,651 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Genentech Inc | COTELLIC | cobimetinib fumarate | TABLET;ORAL | 206192-001 | Nov 10, 2015 | RX | Yes | Yes | 7,803,839*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Genentech Inc | EVRYSDI | risdiplam | FOR SOLUTION;ORAL | 213535-001 | Aug 7, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Genentech Inc | XOFLUZA | baloxavir marboxil | TABLET;ORAL | 210854-003 | Mar 18, 2021 | AB | RX | Yes | Yes | 10,759,814 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |
| Genentech Inc | ROZLYTREK | entrectinib | PELLETS;ORAL | 218550-001 | Oct 20, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Genentech Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 112062778 | ⤷ Start Trial |
| Turkey | 201813877 | ⤷ Start Trial |
| South Africa | 200802075 | ⤷ Start Trial |
| South Korea | 20220165811 | ⤷ Start Trial |
| Slovenia | 2176231 | ⤷ Start Trial |
| Costa Rica | 20140376 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Genentech Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2176231 | SPC/GB20/070 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: ENTRECTINIB OR ISOMERS, TAUTOMERS, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/20/1460 (NI) 20200803; UK PLGB00031/0913 20200803; UK PLGB00031/0914 20200803 |
| 2620436 | 132021000000038 | Italy | ⤷ Start Trial | PRODUCT NAME: BALOXAVIR MARBOXIL O UN SUO SALE O SOLVATO FARMACEUTICAMENTE ACCETTABILE(XOFLUZA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1500, 20210108 |
| 2176231 | 202040047 | Slovenia | ⤷ Start Trial | PRODUCT NAME: ENTRECTINIB OR ISOMERS, TAUTOMERS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NATIONAL AUTHORISATION NUMBER: EU/1/20/1460/001-002; DATE OF NATIONAL AUTHORISATION: 20200731; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 1934174 | 2016/022 | Ireland | ⤷ Start Trial | PRODUCT NAME: COBIMETINIB, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS AND SOLVATES, IN PARTICULAR COBIMETINIB HEMIFUMARATE.; REGISTRATION NO/DATE: EU/1/15/1048/001 20151120 |
| 2620436 | PA2021505,C2620436 | Lithuania | ⤷ Start Trial | PRODUCT NAME: BALOKSAVIRO MARBOKSILAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/20/1500 20210107 |
| 1934174 | SPC/GB16/023 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: COBIMETINIB, INCLUDING A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, IN PARTICULAR COBIMETINIB HEMIFUMARATE; REGISTERED: UK EU/1/15/1048/001(NI) 20151124; UK PLGB 00031/0849 20151124 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
